Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

INOVIQ Signs Sonic Healthcare USA Deal to Validate Ovarian Cancer Test

INOVIQ Limited (IIQ) · Health care

IIQ: $0.145 +7.41% · MC: $18M

INOVIQ has licensed Sonic Healthcare USA to transfer, optimise and validate its EXO-OC ovarian cancer blood test at a New York laboratory. Sonic has an option to pursue a US commercial licence, but has not committed to one; any deal depends on successful validation and further discussions. The agreement follows INOVIQ’s recently announced staged plan to advance the test towards US commercialisation, targeted for early 2028. Separately, newly appointed director Andrew Chapman disclosed relevant interests in approximately 9 million INOVIQ shares.

Source announcements: 2026-11-02 08:32 to 2026-11-02 11:37 Sydney time
Story updated 2026-11-02 11:52 Sydney time
SourcesIIQ signs EXO-OC validation agreement with Sonic HealthcareInitial Director's Interest Notice - A. Chapman
Comments